Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NV\hUpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\OO|IhcA>? NIGwWXBFVVOR M2GxSWlEPTB;MD6wNFAxPyEQvF2= M1K3R|E4QTV4MEiw
K562 NGLpbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS3NkBp MVLEUXNQ NXXiNmF4UUN3ME2wMlAxOSEQvF2= NGDSWZgyPzl3NkC4NC=>
M07e NGnWNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjPVY04OiCq MWrEUXNQ MmPlTWM2OD1yLkCwNVIh|ryP MljuNVc6PTZyOEC=
ALL3 NYHmTVZyS3m2b4TvfIlkKEG|c3H5 NWjl[GtzOC5zzszN Mkj0O|IhcA>? NHfUfZNFVVOR NWj0NlN3UUN3ME2wMlAxODRizszN Ml\RNVk5QDl3NEC=
CML NVTjfYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITTfJUzOCCvaX6= MmDsSG1UVw>? M4fBOGlEPTB;MD6wNFEh|ryP Mlv4NVkzOTlyMU[=
BA/F3 NHmzd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvc|M4OiCq MlXiSG1UVw>? MVjJR|UxRTZwNUi5JO69VQ>? MVKyN|A5QDZ2NB?=
BA/F3 NHXGTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[3NkBp M3nBWmROW09? NIfYU2ZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> MonQNlMxQDh4NES=
BA/F3 NGO3clhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7nOVI4OiCq NYjI[ndrTE2VTx?= MVTJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO MXKyN|A5QDZ2NB?=
BA/F3 NI\2fWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD1O|IhcA>? MojlSG1UVw>? NVHDemU3UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN MX:yN|A5QDZ2NB?=
BA/F3 NYXGUnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\xNmZPPzJiaB?= MXzEUXNQ MkPaTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? NGPUZYQzOzNyMUewNy=>
BA/F3 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yzb|czKGh? MnO1SG1UVw>? NV7NO|FMUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= MXqyN|MxOTdyMx?=
BA/F3 NHLDW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy3NkBp NFz6NpNFVVOR MWTJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? M4XSd|I{OzBzN{Cz
BA/F3 NUXwRY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M136RlczKGh? M376TGROW09? NXHYS3ZvUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MVyyN|MxOTdyMx?=
BA/F3 NVr1XW15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HXPVczKGh? NFTlN|FFVVOR NF7oe|hKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= MoPuNlM{ODF5MEO=
BA/F3 M4nOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG3NkBp NXr0TVlqTE2VTx?= Mo\aTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> NX;L[5d3OjN|MEG3NFM>
BA/F3 M1T5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jKVlczKGh? NFfkZpVFVVOR MVvJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NGrZZVMzOzNyMUewNy=>
BA/F3 M3Lwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NkBp NYHvUYhCTE2VTx?= NYjSbFFTUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? NEXuPWkzOzNyMUewNy=>
BA/F3 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3NkBp Mof2SG1UVw>? Mk\STY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NF\zc|EzOzNyMUewNy=>
T cell NVewVIRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fmfFczKGh? M2f2XmROW09? M{DOPGlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO MoDjNVcyPTR3MUK=
WiDr NVf2[5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjKc244OiCq M3npNGROW09? NWrrNHNvUUN3ME2wMlA2OiEQvF2= M1HxTVE2PjF3NUGy
PC3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLaNmU2PzJiaB?= MUTEUXNQ MUHJR|UxRTBwMEC5OEDPxE1? NWrPdHBqOTV4MUW1NVI>
MDA-MB-231 NH7sUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3npdFczKGh? M1v0e2ROW09? NYe0NIJLUUN3ME2wMlAyOiEQvF2= M3TuTFE2PjF3NUGy
Hs578T NEi5dIhEgXSxdH;4bYMhSXO|YYm= MWC3NkBp MWPEUXNQ NH:zOJpIUTVyPUCuNFMh|ryP M1vBU|I1ODF3M{K3
HMEC M4\NUWN6fG:2b4jpZ{BCe3OjeR?= NXfGO41SPzJiaB?= NWLYXFNOTE2VTx?= MYPHTVUxRTFwODFOwG0> NYLFOmtWOjRyMUWzNlc>
DU145 NX3m[5B2S3m2b4TvfIlkKEG|c3H5 MUe3NkBp MXXEUXNQ NUn6Z5J{T0l3ME2wMlE3KM7:TR?= NFzySYMzPDBzNUOyOy=>
U251 Mn3JR5l1d3SxeHnjJGF{e2G7 NHfaXpk4OiCq MUfEUXNQ MXzHTVUxRTJwOEGg{txO MonmNlQxOTV|Mke=
NCI60 MWPDfZRwfG:6aXOgRZN{[Xl? MYi3NkBp NHz5dVdFVVOR M17lcWdKPTB;NT63JO69VQ>? M1e1TVI1ODF3M{K3
MALME-3M NF;LSm9EgXSxdH;4bYMhSXO|YYm= NEXNWJI4OiCq MX;EUXNQ M374SGdKPTB;Nj62NUDPxE1? NEnBWZozPDBzNUOyOy=>
KM12 M{fYU2N6fG:2b4jpZ{BCe3OjeR?= NVG1cJl7PzJiaB?= MVXEUXNQ MUPHTVUxRTdwNESg{txO MofINlQxOTV|Mke=
SW620 NX:0e3NzS3m2b4TvfIlkKEG|c3H5 NEnqd4Y4OiCq M4nXSmROW09? MlOzS2k2OD16LkSzJO69VQ>? NG\C[JEzPDBzNUOyOy=>
RXF 393NL M2OzSWN6fG:2b4jpZ{BCe3OjeR?= NETYOWs1KGSjeYO= MkPNSG1UVw>? NXXUS4JFUUN3ME2wMlAzOTdizszN MWeyN|I2OzB5NB?=
LXFA 983L MljaR5l1d3SxeHnjJGF{e2G7 MmK5OEBl[Xm| NUnhPIVbTE2VTx?= MlW3TWM2OD1yLkC1OlUh|ryP NWrGbnFPOjN{NUOwO|Q>
PRXF DU145 NX\3Opk6S3m2b4TvfIlkKEG|c3H5 MXi0JIRigXN? M3vDcWROW09? MkHmTWM2OD1yLkC2NlMh|ryP MW[yN|I2OzB5NB?=
PAXF 1657L MWrDfZRwfG:6aXOgRZN{[Xl? M{i0cFQh\GG7cx?= NIniVnlFVVOR NFXDd3lKSzVyPUCuNVIyKM7:TR?= Mlj2NlMzPTNyN{S=
CXF 1103L MnT0R5l1d3SxeHnjJGF{e2G7 M3fYUFQh\GG7cx?= M2jobmROW09? MojlTWM2OD12LkO2JO69VQ>? NV\lNGNLOjN{NUOwO|Q>
GXF251L NFvtfVBEgXSxdH;4bYMhSXO|YYm= M2nuV|Qh\GG7cx?= Mli5SG1UVw>? NVj5PGJPUUN3ME2yMlI2KM7:TR?= NH;rVGczOzJ3M{C3OC=>
NCI-H23 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPmb3M4OiCq MkjRSG1UVw>? NVrPPXdOUUN3ME2yMlI4KM7:TR?= MmDMNlM2OjFyMkC=
HCT116 M1TXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NkBp MoDVSG1UVw>? NV:zVI14UUN3ME2yMlMh|ryP NI\a[3UzOzV{MUCyNC=>
MCF7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPWblhFPzJiaB?= MXPEUXNQ MWfJR|UxRTJwNUeg{txO NX;K[VlIOjN3MkGwNlA>
NCI-H460 M1\r[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnBSWE4OiCq NYX0[JJiTE2VTx?= M2mxd2lEPTB;OD65PUDPxE1? MVqyN|UzOTB{MB?=
DLD1 NGX0VJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP5OGs4OiCq M4j1UWROW09? NWfkZ3p3UUN3ME20MlYh|ryP NYi0XFY1OjN3Nke5OlA>
NCI-H661 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq3NkBp M4jWSmROW09? NUTQNWY1UUN3ME23Mlgh|ryP M{j6NlI{PTZ5OU[w
A549 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHCO|IhcA>? NGLabVhFVVOR MX7JR|UxRThwMjFOwG0> M2LQSVI{PTZ5OU[w
U937 NVXNc|VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp M2rYT2ROW09? NFPpe4ZKSzVyPUGyMlIh|ryP NE\VN3EzOzV4N{m2NC=>
HEK293 NXnTNZBTTnWwY4Tpc44hSXO|YYm= M3\vSVExyqEQvF2= MkT5SG1UVw>? MXvJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= NETlPZEzOjd5ME[xNC=>
HUVEC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPHNE4yPcLizszN NX7Kbmt7PzJiaB?= NUnBZnZlTE2VTx?= MV;JcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= NYrENI1VOjJ6NUO5PVM>
HUVEC M13Ed2Z2dmO2aX;uJGF{e2G7 NH7JNIEyPcLizszN Ml7GO|IhcA>? NXrPTVhjTE2VTx?= NVPWe3N1UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? NFvZNHMzOjh3M{m5Ny=>
Plasmodium falciparum MoHVSpVv[3Srb36gRZN{[Xl? MU[xNOKh|ryP NVHQS291OTVibXnu MYLEUXNQ MXLJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> M4TodVI1PTVyM{Ow
PC3 NFLP[VZHfW6ldHnvckBCe3OjeR?= MYGwMlEh|ryP MkPwOUBp NUTJR5cxTE2VTx?= MlLoTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P NIDreIgyQTR4Mkm3OS=>
DU145 MV;GeY5kfGmxbjDBd5NigQ>? MX2wMlEh|ryP NIKzSGI2KGh? NUHYfmw3TE2VTx?= NILoeHpKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> M4mzWVE6PDZ{OUe1
PC3 MlX1T4lv[XOnIFHzd4F6 NXnlUlViOC5zIN88US=> MnmyOUBp MnS4SG1UVw>? M130bmlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= MnrMNVk1PjJ7N{W=
DU145 MormT4lv[XOnIFHzd4F6 NHjMblgxNjFizszN M1\HZ|UhcA>? NGfVTXFFVVOR MlHzTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NXuxW|VxOTl2NkK5O|U>
PC3 M37EfWtqdmG|ZTDBd5NigQ>? NFXSelMxNjFizszN MYC1JIg> NVrGTnJRTE2VTx?= MXXJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NED2O5gyQTR4Mkm3OS=>
DU145 NXLUTIdzU2mwYYPlJGF{e2G7 NWH3d5h2OC5zIN88US=> NYnhVIZkPSCq NVXlOHNLTE2VTx?= NVTsR|NnUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= MoXyNVk1PjJ7N{W=
Huh7 MYTBcpRqfmm{YXygRZN{[Xl? MoHSNk42KM7:TR?= M3jmdFQh\GG7cx?= MXXEUXNQ NHLvPYFKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NWDRTYN5OTd|NkC2O|Y>
C6/36 M2fubmFvfGm4aYLhcEBCe3OjeR?= NGTXcYgzNjVizszN M{LSUlQh\GG7cx?= M1[wR2ROW09? NWPiUlAzUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= MoLRNVc{PjB4N{[=
U937 NYfi[oxxTnWwY4Tpc44hSXO|YYm= NYjsV49oOSEQvF2= NF3ZeoQyKGh? MYLEUXNQ MnPGVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? M3TZSFE4Pjh2MEm5
U937 MnnvSpVv[3Srb36gRZN{[Xl? MVWxJO69VQ>? NFfIPIsyKGh? MXfEUXNQ NUiyZpFGWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? M3P2cFE4Pjh2MEm5
murine mast cell NWH3T3c3TnWwY4Tpc44hSXO|YYm= MlS3NUDPxE1? NV64[IxQOjRiaB?= NYT6flBMTE2VTx?= NInZXG1KdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= M1HTNFE4Pjh2MEm5
BV-173 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD0TWM2OD1yLkCwNFAxODFyOTFOwG0> NH3GW|lUSU6JRWK=
K-562 NUXvR5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;VRW5UUUN3ME2wMlAxODByMEK2OkDPxE1? M1nCWHNCVkeHUh?=
BL-70 NYK0bHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPzTWM2OD1yLkCwNFAxODh{MjFOwG0> NH3Kb4RUSU6JRWK=
EM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S4UmlEPTB;MD6wNFAxODFyODFOwG0> NXnGSJFPW0GQR1XS
LAMA-84 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHEeWlKSzVyPUCuNFAxODB|MkGg{txO Mn;1V2FPT0WU
MEG-01 NF3XfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMECwNFA6QCEQvF2= MmK1V2FPT0WU
EoL-1-cell NYTKZXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLyTWM2OD1yLkCwNFAyOzFizszN MYTTRW5ITVJ?
CTV-1 M4fJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMECwNFQxPCEQvF2= NXu2bZNCW0GQR1XS
TE-15 NXi0WFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jtWGlEPTB;MD6wNFU5QSEQvF2= NIfVT3dUSU6JRWK=
NOS-1 NYrv[2toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjaTWM2OD1yLkCwOlE{KM7:TR?= MWnTRW5ITVJ?
D-336MG M2nlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEC2N{DPxE1? MUnTRW5ITVJ?
LB1047-RCC MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzpZoNwUUN3ME2wMlAxQTh7IN88US=> MmDPV2FPT0WU
LB996-RCC M4\5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33XTGlEPTB;MD6wNFk6OSEQvF2= M3zsb3NCVkeHUh?=
SW982 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SxWGlEPTB;MD6wNVEyPSEQvF2= MoXHV2FPT0WU
TK10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXVTWRKSzVyPUCuNFEyPzRizszN NEXZSZhUSU6JRWK=
A704 NGXHU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEG0PVEh|ryP M4P0NHNCVkeHUh?=
TE-8 NFXzW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ntXGlEPTB;MD6wNVU4PiEQvF2= MnHlV2FPT0WU
DOHH-2 NI\MfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e3WGlEPTB;MD6wNVcyQSEQvF2= MVvTRW5ITVJ?
HOP-62 NY[zUmZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzXRW5KSzVyPUCuNFE5OzRizszN M1f6XXNCVkeHUh?=
TE-12 M4Cyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEG4OlEh|ryP NXPt[lg1W0GQR1XS
KGN NFvFOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3reFFKSzVyPUCuNFE6PDJizszN M2O3[3NCVkeHUh?=
NCI-H1648 NXPYe4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjNNJJKSzVyPUCuNFIxOTFizszN M2nrNHNCVkeHUh?=
OS-RC-2 NF3zTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXbmlEPTB;MD6wNlA{KM7:TR?= MUjTRW5ITVJ?
GB-1 NXu2e4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnCTWM2OD1yLkCyNVU4KM7:TR?= MnfoV2FPT0WU
RXF393 NGKydFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT0cpE5UUN3ME2wMlAzOzV5IN88US=> MVjTRW5ITVJ?
LC-2-ad NXL5enFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEK1PFYh|ryP Mnm3V2FPT0WU
KS-1 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO3VotKSzVyPUCuNFI4OyEQvF2= NWiwd4E6W0GQR1XS
ETK-1 M1TBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexOmNKSzVyPUCuNFI5OzJizszN MlXTV2FPT0WU
SW954 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q1UWlEPTB;MD6wNlkzPyEQvF2= NGfDbnpUSU6JRWK=
Becker MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Qc2lEPTB;MD6wN|AxOyEQvF2= MofYV2FPT0WU
MZ1-PC NGLyUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7NfIxUUUN3ME2wMlA{OTF7IN88US=> NEK3eYVUSU6JRWK=
ES6 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1yLkCzNVk{KM7:TR?= M1vZVHNCVkeHUh?=
KURAMOCHI NIPmVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEO0PFch|ryP MmW4V2FPT0WU
CGTH-W-1 M{HqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvufJFKSzVyPUCuNFM2PDhizszN MXHTRW5ITVJ?
VA-ES-BJ NYPpeGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SxZmlEPTB;MD6wN|kxOiEQvF2= MkLWV2FPT0WU
LXF-289 M2ntRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjpUWlKSzVyPUCuNFM6PTZizszN M1HRZ3NCVkeHUh?=
MPP-89 NWLsXm9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljPTWM2OD1yLkC0NFQ6KM7:TR?= MnjzV2FPT0WU
SW872 NUW4fndJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvTWM2OD1yLkC0NVYyKM7:TR?= NInlVVRUSU6JRWK=
SNB75 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfOOWs2UUN3ME2wMlA1PDN3IN88US=> NX;DXHJ[W0GQR1XS
PSN1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTlfnN{UUN3ME2wMlA1PDd2IN88US=> MkLBV2FPT0WU
LB831-BLC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Bd2lEPTB;MD6wOFYxQSEQvF2= M3fpVHNCVkeHUh?=
MFH-ino M4PIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v0W2lEPTB;MD6wOFczPCEQvF2= NXWyOXpMW0GQR1XS
TGBC24TKB NFu3NldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMES3OlEh|ryP NUDyU2x3W0GQR1XS
A388 M2PoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfpTWM2OD1yLkC1NFk2KM7:TR?= NE\qR4JUSU6JRWK=
BB30-HNC NV3zbHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP5NpVKSzVyPUCuNFU1OzdizszN MXvTRW5ITVJ?
GI-ME-N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBWmlEPTB;MD6wOlEyQCEQvF2= MnvTV2FPT0WU
TGBC1TKB M4rsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v0PWlEPTB;MD6wOlE3PCEQvF2= NFTocYlUSU6JRWK=
TE-10 NETKWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TxbGlEPTB;MD6wOlM2PyEQvF2= MlrTV2FPT0WU
A498 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml25TWM2OD1yLkC3Nlg1KM7:TR?= NEPPfWNUSU6JRWK=
TE-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[0VWlEPTB;MD6wO|g2QCEQvF2= NWPiVmJFW0GQR1XS
BB65-RCC NYfzcYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWPGRnUUN3ME2wMlA5OjJ5IN88US=> NFzVO3pUSU6JRWK=
C2BBe1 NIrITVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEizNFgh|ryP M2jMSHNCVkeHUh?=
NCI-H747 NWe2WWxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK0TWM2OD1yLkC4N|YzKM7:TR?= MkfCV2FPT0WU
IST-MES1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvRTWM2OD1yLkC4OVUzKM7:TR?= NUTyNG56W0GQR1XS
KALS-1 NVHlcGRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\X[2lEPTB;MD6wPVQ6KM7:TR?= M1uxSXNCVkeHUh?=
GCIY NF7HOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHFTnNbUUN3ME2wMlA6PjV4IN88US=> MnPTV2FPT0WU
RL95-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTCeHJQUUN3ME2wMlExOzhizszN NV[xPY5PW0GQR1XS
TE-1 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnRNIFKSzVyPUCuNVA2PCEQvF2= M3XneHNCVkeHUh?=
NCI-H1355 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUGwNlgh|ryP MXTTRW5ITVJ?
SW962 M2fJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMUGyPVIh|ryP MlLoV2FPT0WU
KLE MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn2ZVZ7UUN3ME2wMlEyOzF5IN88US=> M1K4cHNCVkeHUh?=
MC116 M4jieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\NfYZKSzVyPUCuNVE1OSEQvF2= NXHPNHF2W0GQR1XS
NMC-G1 NFS2U2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMUG2NFYh|ryP MWTTRW5ITVJ?
KU812 NWKxNJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnwSWJRUUN3ME2wMlEyQDh|IN88US=> Ml;uV2FPT0WU
COLO-829 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMUKyNVMh|ryP MX3TRW5ITVJ?
NTERA-S-cl-D1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tvc2lEPTB;MD6xNlI5OyEQvF2= M4fVc3NCVkeHUh?=
IST-MEL1 NVHXRmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTzTWM2OD1yLkGzOFUh|ryP NXzYWnlwW0GQR1XS
MLMA NFPzV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TSeWlEPTB;MD6xOFA{OiEQvF2= NYTr[3dqW0GQR1XS
LS-123 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S5XGlEPTB;MD6xOFA3PCEQvF2= MorjV2FPT0WU
LB2518-MEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjKTWM2OD1yLkG0NVYzKM7:TR?= NG\NfGFUSU6JRWK=
NB69 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMUS0N|Yh|ryP NIXzXI5USU6JRWK=
8-MG-BA NUXNNHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\leWlEPTB;MD6xOVQ2QCEQvF2= NXfuVmtqW0GQR1XS
K5 M1iwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMU[0PFkh|ryP MkD0V2FPT0WU
KINGS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMU[2OlYh|ryP MX;TRW5ITVJ?
SF268 NEPFPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMUe0NFQh|ryP NGfGfHBUSU6JRWK=
PF-382 M1nGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXzTWM2OD1yLkG3Olc5KM7:TR?= MlXaV2FPT0WU
SH-4 NIPBTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfIbVFbUUN3ME2wMlE5PDF|IN88US=> MUHTRW5ITVJ?
NALM-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fOS2lEPTB;MD6xPVI6PSEQvF2= MXnTRW5ITVJ?
CP66-MEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUm1N|Eh|ryP M4\uU3NCVkeHUh?=
697 M1myNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PMemlEPTB;MD6xPVk5PyEQvF2= MXrTRW5ITVJ?
CP67-MEL M3XQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vjd2lEPTB;MD6yNFQ5QCEQvF2= MVLTRW5ITVJ?
DSH1 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP1bnJCUUN3ME2wMlI1ODBzIN88US=> MlrPV2FPT0WU
HCE-4 NEfzOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn76TWM2OD1yLkK2OFM6KM7:TR?= MWfTRW5ITVJ?
MZ2-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknHTWM2OD1yLkK4OVM4KM7:TR?= NFv4ZXRUSU6JRWK=
BL-41 NXi0VnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP4TWM2OD1yLkK5NVI{KM7:TR?= NYfERoJJW0GQR1XS
HUTU-80 NFrwTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwM{G0NkDPxE1? NVvIV2lHW0GQR1XS
LOXIMVI MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwM{G1NFMh|ryP NIK1eYZUSU6JRWK=
no-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHJVWZ1UUN3ME2wMlMyQTNzIN88US=> MVLTRW5ITVJ?
KARPAS-422 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyTWM2OD1yLkOzPVk4KM7:TR?= NELwNoxUSU6JRWK=
SW684 NYjUWY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33lNmlEPTB;MD6zOFk5KM7:TR?= NFzSRYFUSU6JRWK=
SF126 NUX4UmJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYVGlEPTB;MD6zOVQyKM7:TR?= NXTqRpM4W0GQR1XS
D-263MG M3Xsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K1SmlEPTB;MD6zOlIzPCEQvF2= NVfJbpk{W0GQR1XS
OVCAR-4 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TNTWlEPTB;MD6zO|Q{OyEQvF2= NVfEW5R5W0GQR1XS
BB49-HNC NYLNVFJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1Zo9KSzVyPUCuN|g2QTlizszN MVzTRW5ITVJ?
ONS-76 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnaVWxKSzVyPUCuOFI6PTFizszN M3fJbnNCVkeHUh?=
MZ7-mel M{jvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK1NJlKSzVyPUCuOFc6OTFizszN NW\scIVyW0GQR1XS
RCC10RGB NYLFVJRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXNclV4UUN3ME2wMlQ6OTFizszN M{PPWHNCVkeHUh?=
BOKU NHTo[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrwVHlKSzVyPUCuOFkyOzNizszN MofFV2FPT0WU
no-11 NYnGRoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNUCyNlgh|ryP NVv3dJFyW0GQR1XS
IST-SL2 NHrvclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K2cWlEPTB;MD61NFMxOiEQvF2= M2fXdXNCVkeHUh?=
RKO MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnlTWM2OD1yLkWyPVY3KM7:TR?= MX7TRW5ITVJ?
HT-144 M4K1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnSZ5FYUUN3ME2wMlU{PjB7IN88US=> NWOzR2hHW0GQR1XS
NCI-H446 M3L3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNkK3OkDPxE1? NVPTOGZQW0GQR1XS
QIMR-WIL M{KwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInWT2lKSzVyPUCuO|A3OjlizszN NXf3OZl6W0GQR1XS
MHH-PREB-1 NYHWOXRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwN{S0Olkh|ryP M{LIenNCVkeHUh?=
EW-16 M{DJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHtTWM2OD1yLke2NVc5KM7:TR?= NUG0dmlpW0GQR1XS
EW-24 NIPlZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3nPHpKSzVyPUCuO|gyPjVizszN NGTWWW1USU6JRWK=
LB373-MEL-D M4Kzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPmc2dKSzVyPUCuPFI2ODhizszN MoTqV2FPT0WU
TE-9 NYDpXIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwOEe1N|Ih|ryP M4HuXnNCVkeHUh?=
A3-KAW NXzTR2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwOUi0OVIh|ryP MULTRW5ITVJ?
A101D NUCwXG5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\5bmxPUUN3ME2xMlA{ODR|IN88US=> NVP3bGl2W0GQR1XS
OCUB-M M1zsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;vcpFKSzVyPUGuNFQ1OTJizszN M{T1fHNCVkeHUh?=
ES4 NInSV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTHTWM2OD1zLkC1NVQ2KM7:TR?= M1PZ[HNCVkeHUh?=
TE-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwMkGyNlYh|ryP NU\yV5dpW0GQR1XS
D-502MG M4q0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMkOzO|Yh|ryP NX\leFU2W0GQR1XS
KNS-42 NEP6RnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHZR2VKSzVyPUGuNlQ1OTJizszN Mn;uV2FPT0WU
SNU-C2B NGDub5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\DTWM2OD1zLkOwOVg6KM7:TR?= NEfLUXNUSU6JRWK=
NCI-H1838 M1XuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPOUXhrUUN3ME2xMlMxPzN|IN88US=> NVm1R2loW0GQR1XS
NKM-1 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3LTWM2OD1zLkOwPFU6KM7:TR?= MoDmV2FPT0WU
GI-1 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe4bmJnUUN3ME2xMlM3OjJizszN NW\IbWZCW0GQR1XS
NB5 M1jpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm1TWM2OD1zLkO5PFI4KM7:TR?= M{P1NHNCVkeHUh?=
CAS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fCcmlEPTB;MT60NFk6OiEQvF2= NV;NPWVTW0GQR1XS
HCE-T NXzm[FRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0TGlEPTB;MT61OlcyPCEQvF2= NF7yZ4JUSU6JRWK=
SBC-1 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwNUe5PFQh|ryP NI\z[XRUSU6JRWK=
JiyoyeP-2003 NWLBc4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzDdpAzUUN3ME2xMlc{PDZ4IN88US=> NXy3eYp{W0GQR1XS
TE-5 NHTNNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP1TWM2OD1zLke5NVM6KM7:TR?= MVzTRW5ITVJ?
CAN MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnftTWM2OD1zLkiyNlUzKM7:TR?= MVzTRW5ITVJ?
SK-UT-1 NXPWb5VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DUUmlEPTB;Mj6xOlY6OyEQvF2= NH7tOlBUSU6JRWK=
JVM-2 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki1TWM2OD1{LkO2Nlg1KM7:TR?= NIDicIZUSU6JRWK=
LB771-HNC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\TTWM2OD1{LkW3OVUyKM7:TR?= MWjTRW5ITVJ?
NCCIT NEL0eFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HVdWlEPTB;Mj64OlYyPiEQvF2= NYKzXG1SW0GQR1XS
NCI-H2126 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnpNVJKSzVyPUKuPFc2PTJizszN NEfKcXFUSU6JRWK=
Calu-6 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjFTWM2OD1|LkC1O|QyKM7:TR?= M4qwVXNCVkeHUh?=
SK-LMS-1 NVO1S4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\HTmlEPTB;Mz6xNVg5PiEQvF2= NVrFR5ZGW0GQR1XS
ARH-77 M{Twcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jNWGlEPTB;Mz60OlkyPSEQvF2= NH7JPVBUSU6JRWK=
NB17 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH32dXFKSzVyPUOuOlM5PDdizszN NF7LN5lUSU6JRWK=
A253 NUfKblRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TlcmlEPTB;Mz63N|I1PiEQvF2= MX\TRW5ITVJ?
OPM-2 M4K3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjQcVlPUUN3ME20MlI4Pjh3IN88US=> NFvabnlUSU6JRWK=
MV-4-11 M2j3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRwM{[0OVQh|ryP NWHGb21zW0GQR1XS
SR Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD12LkS5PVU1KM7:TR?= M2j1UXNCVkeHUh?=
KG-1 NVvpNIFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;GSGpKSzVyPUSuOlA5PDVizszN NFf4OHpUSU6JRWK=
OCI-AML2 NVvpTZg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDOTWM2OD13Lki2NVU1KM7:TR?= M{HINHNCVkeHUh?=
D-247MG NF;zTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjRTWM2OD14LkGyOVE6KM7:TR?= NV\zT|JmW0GQR1XS
DJM-1 NHn0bZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nNO2lEPTB;Nj60PFU2QCEQvF2= M3r6bnNCVkeHUh?=
RPMI-6666 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C3RWlEPTB;Nz6yO|A3PyEQvF2= MXrTRW5ITVJ?
KARPAS-45 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fOSmlEPTB;Nz61NVY4OSEQvF2= MlviV2FPT0WU
LP-1 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Zco9KSzVyPUeuOVQ4QDJizszN MVLTRW5ITVJ?
RS4-11 NWHU[JFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrScpRKSzVyPUeuOlU4QDdizszN NXz0XllrW0GQR1XS
DU-4475 M4jJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRThwMkG2OVIh|ryP MlP5V2FPT0WU
MONO-MAC-6 M1nOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfxSG0xUUN3ME24MlI4ODZ4IN88US=> M161NXNCVkeHUh?=
NCI-SNU-16 M1KwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PPc2lEPTB;OD61OlEzQCEQvF2= M{DwT3NCVkeHUh?=
SJSA-1 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HGdGlEPTB;OD63NlgxPSEQvF2= MkfEV2FPT0WU
MMAC-SF NI\vPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW4TWM2OD16Lke5N|A4KM7:TR?= NF;CeJNUSU6JRWK=
SK-NEP-1 NUXVcII6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\VWoo1UUN3ME24Mlg6OTV3IN88US=> M4DDZXNCVkeHUh?=
J-RT3-T3-5 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrkTWM2OD16Lkm2OVI6KM7:TR?= M{TEN3NCVkeHUh?=
SKM-1 M1vQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELEbY5KSzVyPUmuNFE4OzRizszN NHvVOIhUSU6JRWK=
LB2241-RCC NFT5e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTlwMEKwNVIh|ryP Mm\4V2FPT0WU
SIG-M5 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnNTIt[UUN3ME25MlAzPDl|IN88US=> NHfxS2VUSU6JRWK=
EVSA-T MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37aNmlEPTB;OT6yO|c6OyEQvF2= NXfJeIFJW0GQR1XS
GT3TKB NIX4[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTOTWM2OD17LkO1OVQ3KM7:TR?= MUjTRW5ITVJ?
NB6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH0TWM2OD17LkmyNlU6KM7:TR?= NIHSd5BUSU6JRWK=
EHEB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13R[mlEPTB;MUCuNFY2PiEQvF2= M4fp[HNCVkeHUh?=
HEL NVrsd5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXDfmNKSzVyPUGwMlQ4PzZizszN MmXzV2FPT0WU
ALL-PO NFTSUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;mOW1KSzVyPUGwMlc6OzhizszN M{TiXXNCVkeHUh?=
TGW NXnzdGVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFzLkK4Nlgh|ryP MkL5V2FPT0WU
BC-3 NF3yfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLBTWM2OD1zMj6xNVM5KM7:TR?= M3XMd3NCVkeHUh?=
IA-LM MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF{LkS0OFUh|ryP NFfuTJZUSU6JRWK=
UACC-257 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HWbWlEPTB;MUKuPVE6QCEQvF2= MYjTRW5ITVJ?
KP-N-YS M{DKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDhbIxKSzVyPUGyMlkzQDNizszN M{[3ZXNCVkeHUh?=
Raji NV;odYVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTiNoZKSzVyPUGzMlc1QTdizszN M1ixWnNCVkeHUh?=
SF539 M{jHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV74[4t{UUN3ME2xN{45PTV5IN88US=> MYDTRW5ITVJ?
DMS-153 NH;rOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L0XmlEPTB;MUSuNFAzQCEQvF2= M3HVd3NCVkeHUh?=
L-540 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHZdItMUUN3ME2xOU4xPjd{IN88US=> NXP5RnpbW0GQR1XS
MN-60 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjxT5pKSzVyPUG1MlE6PzlizszN MlPwV2FPT0WU
RPMI-8866 NECzSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LPbmlEPTB;MUeuOFQ2PCEQvF2= M{XjT3NCVkeHUh?=
NCI-H510A MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\iTWM2OD1zOT6zPVc{KM7:TR?= MU\TRW5ITVJ?
NB13 M4LXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHVTWM2OD1zOT60PFc4KM7:TR?= MX;TRW5ITVJ?
HAL-01 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF7Lke1OFMh|ryP MmiwV2FPT0WU
NCI-H720 NUnOOGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJyLkK3N|Mh|ryP MnPEV2FPT0WU
REH NX23SnBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJyLk[zOVch|ryP NH;OUolUSU6JRWK=
KNS-81-FD M1[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrOdYZKSzVyPUKzMlE1PiEQvF2= NXH5OWdvW0GQR1XS
HC-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvNVlkUUN3ME2yOE42PTVzIN88US=> NGDVOnhUSU6JRWK=
NCI-H2141 NHXa[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInOc4FKSzVyPUK0Mlc4PTRizszN MlPDV2FPT0WU
MOLT-4 M3vnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M134R2lEPTB;Mk[uOlc2OyEQvF2= M3LZNHNCVkeHUh?=
OMC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ5LkG0NlIh|ryP MX3TRW5ITVJ?
LC-1F NUWxXYhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ5LkOyOFUh|ryP NGHROZBUSU6JRWK=
NCI-H1304 NVvqeWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ6LkG2Nlgh|ryP MmqwV2FPT0WU
BC-1 M122[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ6Lk[1NUDPxE1? MWXTRW5ITVJ?
NCI-H64 M3vs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ7Lk[yOVMh|ryP Mn;kV2FPT0WU
MOLT-16 NULmcodZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ7Lk[yPVIh|ryP M4rTVHNCVkeHUh?=
U-87-MG MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO0TWM2OD1|MD63OlYh|ryP MkfPV2FPT0WU
GAK M{HX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTkfWhkUUN3ME2zNU4zPjh4IN88US=> NWDO[HB2W0GQR1XS
ES8 NIrHVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN{LkGyOVIh|ryP M3;uPXNCVkeHUh?=
HCC1599 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHtNWR3UUN3ME2zNk4{OzJ3IN88US=> MlTUV2FPT0WU
EB-3 NHrrVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPLXWhKSzVyPUO0MlMyOTdizszN NYHpbW5oW0GQR1XS
HCC1187 NGnKPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3zWFlOUUN3ME2zOU45ODV{IN88US=> MV7TRW5ITVJ?
SK-PN-DW NVnDSWVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPWWWdIUUN3ME2zOk4yQTR|IN88US=> NEPjfWFUSU6JRWK=
JVM-3 NUPBcW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjmZmlKSzVyPUO3MlI{OzhizszN NUnXclJUW0GQR1XS
HCC2157 MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\PTIViUUN3ME2zO{46QTR4IN88US=> M4O5c3NCVkeHUh?=
A4-Fuk MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFizdoVKSzVyPUO4MlExODlizszN NGjzdWhUSU6JRWK=
COR-L279 NXzBN5dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v3RmlEPTB;NECuNlg2OSEQvF2= MXHTRW5ITVJ?
DEL M4XVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzOTWM2OD12MT65NFg3KM7:TR?= Mk[zV2FPT0WU
NCI-H1395 NI\BNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDUTWM2OD12Mj6wNVY{KM7:TR?= Ml;4V2FPT0WU
MHH-NB-11 NHXwW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfiTYZKSzVyPUSzMlA5OThizszN NHfv[21USU6JRWK=
NCI-H2107 NWfCOlU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DZO2lEPTB;NEOuOFg1PiEQvF2= M4eyXXNCVkeHUh?=
NEC8 M3PZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjjXIp{UUN3ME20OE4{OzZizszN M3HjOHNCVkeHUh?=
COLO-684 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYntOlhwUUN3ME20Ok4zOjV6IN88US=> MoHaV2FPT0WU
LS-411N MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonYTWM2OD12OD60O|Q5KM7:TR?= NWXJW5l3W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID